The warrant exercise is a procedural step that does not change the activist's economic exposure or strategic position. Watch for the Phase 3 protocol submission for PDS0301, which would trigger the $10 million milestone closing and potentially increase Nant Capital's stake further.
Drugs in focus
PDSB drug pipeline →PDS0301
◆ Mixed Named in this SC 13D/A- Impact
- Phase
- Phase 2
- Time to market
- PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
- Next catalyst
- None dated
What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $0.9800entry
- T+1 · 4d ago −10.96%α −10.60% · $0.8726
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Nant Capital exercised its 17,699,115 Common Warrants in full, converting them into 9,851,119 shares of common stock and 7,847,996 Pre-Funded Warrants for an aggregate exercise price of $3.89 million. The stake remains at 19.9% due to a beneficial ownership blocker, and the Pre-Funded Warrants (30,240,892 total) are not exercisable within 60 days. The activist's board representation and option to negotiate an exclusive license for PDS0101 remain unchanged, and a $10 million milestone closing tied to a Phase 3 protocol submission for PDS0301 is still pending.
Key Financial Metrics
Key Facts
- Nant Capital exercised 17,699,115 Common Warrants on November 9, 2026, for $3,891,215.46.
- Exercise converted into 9,851,119 common shares and 7,847,996 Pre-Funded Warrants.
- Nant Capital now holds 22,856,453 common shares (19.9% of 114,856,548 outstanding) and 30,240,892 Pre-Funded Warrants.
- All Pre-Funded Warrants are subject to a 19.9% beneficial ownership blocker and are not exercisable within 60 days.
- No Common Warrants remain outstanding.
- Board representation (two seats) and the PDS0101 option to negotiate remain in place.
- A $10 million milestone closing is contingent on submission of a Phase 3 protocol for PDS0301 to the FDA.
- No other transactions in common stock during the past 60 days.
Financial Impact
Nant Capital paid $3.89 million to exercise warrants; no new capital raised for the company beyond the initial PIPE. The $10 million milestone closing is still pending.
Risk Factors
- The Pre-Funded Warrants remain subject to a 19.9% blocker, limiting future dilution from this holder.
- The company is pre-revenue with a history of dilutive offerings and cash burn, as noted in the prior 10-K.
- The $10 million milestone closing is contingent on FDA protocol submission, which may be delayed or not occur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001193125-26-456632 |
| Document: 0001193125-26-456632-index.html | 0001193125-26-456632 |
| Document: 0001193125-26-456632.txt | 0001193125-26-456632 |
Track record
28 reports on PDSB
7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Viewing Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers